Originally developed for in-house testing, the company’s Advanced peripheral blood Hematopoietic Chimera (“ApbHC”) is a novel type of humanised mouse that presents several advantages over existing mouse models. It has applications for disease modelling and drug development, and potentially for biodefence.
ApbHC can be used for testing multi-specific antibodies, including Hemogenyx Pharmaceuticals’ own bi-specific CDX antibody for the elimination of acute myeloid leukemia (AML) and other blood disorders as well as the conditioning of patients for bone marrow transplantation. ApbHC may also be used for the development and testing of new cell therapies involving immune cell reprogramming, such as CAR-T. The ApbHC is already being used for the modelling of autoimmune diseases, such as lupus, with a goal of developing fundamentally new treatments for those diseases. Furthermore, the ApbHC could potentially be used as a tool for the rapid development and/or isolation of human antibodies against unknown human-specific pathogens (biodefence applications).
The major advantage of the ApbHC is the absence of Graft versus Host Disease, a disease that complicates and often renders impossible the efficient use of peripheral blood mononuclear cells in transplanted mice.
The ApbHC is proving to be of considerable interest to other drug developers. The group has signed a number of collaboration agreements to develop mouse models of diseases and test drugs.
Hemogenyx Pharmaceuticals has established a subsidiary, Immugenyx LLC, to further develop and commercialise the ApbHC. Immugenyx is also leveraging the unique properties of AHC itself to discover and develop novel treatments for autoimmune diseases.